文献速递神经肿瘤

IDH突变胶质瘤中MGMT启动子甲基化的预后意义

Prognostic significance of O6-methylguanine-DNA methyltransferase promoter methylation status in isocitrate dehydrogenase-mutant glioma.
PubMed 文献 · Neuro Oncol · 2026-01-01

本研究回顾性纳入520例IDH突变胶质瘤成人患者,评估MGMT启动子甲基化及其他临床、分子和影像变量的生存影响。多因素分析显示MGMT启动子甲基化与总生存(P=0.11)和无进展生存(P=0.74)均无显著关联,而CDKN2A/B纯合缺失和整合分级4是星形细胞瘤总生存的强预测因子,最大程度切除和放疗是无进展生存的强预后因素。

要点

  • IDH突变胶质瘤中MGMT启动子甲基化与总生存和无进展生存均无显著关联。
  • CDKN2A/B纯合缺失和整合分级4是星形细胞瘤总生存的强预测因子。
  • 最大程度切除和放疗是整个队列无进展生存的强预后因素。

核心结论

  • 在本IDH突变胶质瘤队列中,MGMT启动子甲基化未显示预后或预测价值。
  • CDKN2A/B状态和切除程度是结局的强预测因子。

研究设计与样本

  • 回顾性评估520例连续成人IDH突变胶质瘤患者,来自两家大型学术机构,涵盖任何组织学分级。
  • MGMT启动子甲基化通过甲基化特异性聚合酶链反应(PCR)分析评估。
  • 采用对数秩检验和Cox比例风险模型评估临床、分子和影像特征与总生存(OS)及无进展生存(PFS)的关联。

主要发现

  • 中位年龄36.6岁;MGMT启动子甲基化占70%,未甲基化占30%。
  • 多因素分析中MGMT启动子甲基化与OS(P=0.11)或PFS(P=0.74)无显著关联。
  • 星形细胞瘤中CDKN2A/B纯合缺失[HR=3.26(1.47,7.23),P=.006]和整合分级4分类[HR=2.08(1.06,4.67),P=.048]是OS的强预测因子。
  • 整个队列中最大程度切除[HR=0.06(0.01,0.57),p=0.016]和放疗[HR=0.41(0.18,0.91),P=.03]是PFS的强预后因素。
  • 2级和3级胶质瘤中,强化病灶最大程度切除[HR=0.17(0.05,0.96),P=.014]和放疗[HR=0.47(0.19,0.65),P=.046]与PFS强相关。

临床怎么用

  • 在IDH突变胶质瘤中,MGMT启动子甲基化不宜作为独立的预后或预测标志物。
  • 应关注CDKN2A/B状态和整合分级以评估星形细胞瘤总生存风险。
  • 最大程度切除和放疗与改善无进展生存相关,尤其对于2级和3级胶质瘤。

局限性

  • 回顾性研究设计。
  • MGMT启动子甲基化通过甲基化特异性PCR评估,未提及其他方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prognostic and predictive value of O6-methylguanine-DNA methyltransferase promoter (MGMTp) methylation is not well established in isocitrate dehydrogenase (IDH)-mutant gliomas. This study evaluates the survival impact of MGMTp and other clinical, molecular, and radiologic variables in low-grade and high-grade IDH-mutant gliomas. METHODS: We retrospectively evaluated 520 consecutive adult patients treated for an initial diagnosis of IDH-mutant glioma, of any histological grade, at two large academic institutions. MGMTp methylation was evaluated by methylation-specific polymerase chain reaction (PCR) analysis. Log-rank test and Cox proportional hazards model were applied to evaluate the association of clinical, molecular, and radiological characteristics with overall survival (OS) and progression-free survival (PFS). RESULTS: Median age was 36.6 years; MGMTp was methylated in 70% and unmethylated in 30%. MGMTp methylation was not significantly associated with OS (P = 0.11) or PFS (P = 0.74) on multivariate analyses. Cyclin dependent kinase inhibitor 2A/B (CDKN2A/B) homozygous deletion [HR = 3.26 (1.47, 7.23), P = .006] and an integrated grade 4 classification [HR = 2.08 (1.06, 4.67), P = .048] were strong predictors of OS in astrocytoma, whereas maximal resection [HR = 0.06 (0.01, 0.57), p = 0.016] and radiation [HR = 0.41 (0.18, 0.91), P = .03] were strong prognosticators for PFS in the entire cohort. Maximal resection of the enhancing disease [HR = 0.17 (0.05, 0.96), P = .014] and radiation [HR = 0.47 (0.19, 0.65), P = .046] were strongly associated with PFS in grade 2 and 3 gliomas. CONCLUSION: MGMTp methylation was not associated with a prognostic or predictive value in our IDH-mutant glioma cohort. CDKN2A/B status and extent of resection were strong predictors of outcomes.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Youssef G, Aquilanti E, Miller JJ, et al. Prognostic significance of O6-methylguanine-DNA methyltransferase promoter methylation status in isocitrate dehydrogenase-mutant glioma. Neuro Oncol. 2026. PMID: 41397912. doi:10.1093/neuonc/noaf287

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。